Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Double-blind Placebo-controlled Efficacy Trial of EVO100 Vaginal Gel for the Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

NCT04553068 is registered in ClinicalTrials.gov with Evofem Inc. as lead sponsor.

NCT NCT04553068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04553068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Double-blind Placebo-controlled Efficacy Trial of EVO100 Vaginal Gel for the Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
Lead sponsor
Evofem Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 15, 2020
Completion date
July 28, 2022
Enrollment
1,892 (actual)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

chlamydia, gonorrhea, sexually transmitted diseases